TAR
0.024
140%
1TT
0.001
-50%
CNJ
0.076
52%
BIT
0.002
-33.3%
NAE
0.003
50%
M2R
0.002
-33.3%
ECS
0.007
40%
KLV
0.005
-28.6%
GG1
0.21
31.3%
APCR
0.003
-25%
EOS
6.46
28.9%
OVT
0.003
-25%
CTO
0.014
27.3%
EXT
0.008
-20%
AAU
0.01
25%
MRQ
0.004
-20%
FTI
0.25
25%
PER
0.008
-20%
MML
0.032
23.1%
RDN
0.004
-20%
ENX
0.28
21.7%
VEN
0.004
-20%
EWC
0.056
21.7%
W2V
0.008
-20%
TEM
0.006
20%
AGR
0.018
-18.2%
AGD
0.13
18.2%
NES
0.005
-16.7%
AX8
0.007
16.7%
ARC
0.096
-16.5%
BNL
0.007
16.7%
TSK
0.115
-14.8%
ENV
0.007
16.7%
CRD
0.6
-14.3%
LCL
0.007
16.7%
HHR
0.006
-14.3%
SER
0.007
16.7%
PIM
0.06
-14.3%
BEZ
0.05
16.3%
AUV
0.013
-13.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CYP Phase 2 Trial approved

Cynata Therapeutics (ASX:CYP), a clinical-stage biotechnology company specialising in cell therapeutics, has received regulatory and ethics approval to commence its Phase 2 clinical trial at clinical centres in Turkey | ASX announcement: https://app.sharelinktechnologies.com/announcement/asx/e0fa6ac7f7a6ddf39eef8d4299365c12 #shorts